Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. China
  4. Shanghai Stock Exchange
  5. Shanghai Fosun Pharmaceutical (Group) Co., Ltd.
  6. News
  7. Summary
    600196   CNE000000X38

SHANGHAI FOSUN PHARMACEUTICAL (GROUP) CO., LTD.

(600196)
  Report
SummaryChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Shanghai Fosun Pharmaceutical : Fosun Pharma to provide factory with annual capacity of 1 bln doses of BioNTech's COVID-19 vaccine

05/09/2021 | 09:08am EDT

BEIJING, May 9 (Reuters) - China's Shanghai Fosun Pharmaceutical said its subsidiary has agreed to provide a factory with an annual capacity to make up to 1 billion doses of the COVID-19 vaccine developed by BioNTech .

This marks a step closer for China to have localized manufacturing capability for the German firm's vaccine. Five domestically-developed COVID-19 vaccines are being used in the country, while no foreign ones have gained regulatory approval.

BioNTech, which is also partnering with Pfizer to produce and distribute the vaccine in markets outside China, Hong Kong, Macau and Taiwan, said last month that it expects to win approval from the Chinese health authority "by July at the latest" for the product.

The factory is part of a joint venture between Fosun Pharmaceutical Industrial and BioNTech, in which the two companies will hold 50% stake each, Shanghai Fosun Pharma said in a filing on Sunday.

BioNTech has agreed to license relevant manufacturing technology and know-how to the JV with Fosun, the filing said. (Reporting by Roxanne Liu and Ryan Woo; editing by David Evans)


© Reuters 2021
All news about SHANGHAI FOSUN PHARMACEUTICAL (GROUP) CO., LTD.
07/28SHANGHAI FOSUN PHARMACEUTICAL : An announcement has just been published by the i..
PU
07/19Sisram Medical Seeks $80 Million in Private Placement; Shares Fall 6%
MT
07/19SHANGHAI FOSUN PHARMACEUTICAL : Voluntary announcement entering into the placing..
PU
07/19SHANGHAI FOSUN PHARMACEUTICAL (GROUP : Ex-dividend day for final dividend
FA
07/14SINOVAC BIOTECH : Fosun-BioNTech COVID-19 vaccine completes China regulator revi..
RE
07/14MARKET CHATTER : BioNTech's COVID-19 Vaccine Advances to Administration Review i..
MT
07/14SHANGHAI FOSUN PHARMACEUTICAL : Poll results of the resolution proposed at the 2..
PU
07/13Hong Kong says no personal data shared in vaccine deal with Fosun
RE
07/13Sisram Medical Limited completed the acquisition of Shanghai Foshion Medical ..
CI
07/12Politics, health collided in Taiwan's tortured BioNTech vaccine talks
RE
More news
Financials
Sales 2021 40 184 M 6 220 M 6 220 M
Net income 2021 4 372 M 677 M 677 M
Net Debt 2021 15 917 M 2 464 M 2 464 M
P/E ratio 2021 48,2x
Yield 2021 0,63%
Capitalization 165 B 25 482 M 25 485 M
EV / Sales 2021 4,49x
EV / Sales 2022 3,98x
Nbr of Employees 32 258
Free-Float 58,8%
Chart SHANGHAI FOSUN PHARMACEUTICAL (GROUP) CO., LTD.
Duration : Period :
Shanghai Fosun Pharmaceutical (Group) Co., Ltd. Technical Analysis Chart | 600196 | CNE000000X38 | MarketScreener
Technical analysis trends SHANGHAI FOSUN PHARMACEUTICAL (GROUP) CO., LTD.
Short TermMid-TermLong Term
TrendsNeutralBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 9
Last Close Price 81,88 CNY
Average target price 57,08 CNY
Spread / Average Target -30,3%
EPS Revisions
Managers and Directors
Xiao Hui Guan Executive President & Chief Financial Officer
Yu Qing Chen Co-President
Ke Xin Wang Co-President
Dong Ming Li Co-President
Yi Fang Wu Chairman